Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan

被引：0

作者：

Chen-Hua Liu

Po-Yueh Chen

Jyh-Jou Chen

Ching-Chu Lo

Wei-Wen Su

Kuo-Chih Tseng

Chun-Jen Liu

Chia-Sheng Huang

Ke-Jhang Huang

Sheng-Shun Yang

Cheng-Yuan Peng

Ming-Chang Tsai

Wei-Yu Kao

Chi-Yang Chang

Yu-Lueng Shih

Yu-Jen Fang

Chi-Yi Chen

Pei-Lun Lee

Jow-Jyh Huang

Pei-Yuan Su

Chi-Wei Tseng

Chien-Ching Hung

Chung-Hsin Chang

Yi-Jie Huang

Hsueh-Chou Lai

Chun-Chao Chang

Fu-Jen Lee

Tsai‐Yuan Hsieh

Jia-Horng Kao

机构：

[1] National Taiwan University Hospital,Department of Internal Medicine

[2] National Taiwan University Hospital,Hepatitis Research Center

[3] National Taiwan University Hospital,Department of Internal Medicine

[4] Ditmanson Medical Foundation Chiayi Christian Hospital,Division of Gastroenterology and Hepatology, Department of Internal Medicine

[5] Chi-Mei Medical Center,Division of Gastroenterology and Hepatology

[6] St. Martin De Porres Hospital,Department of Internal Medicine

[7] Changhua Christian Hospital,Division of Gastroenterology, Department of Internal Medicine

[8] Dalin Tzu Chi Hospital,Department of Internal Medicine

[9] Tzuchi University,School of Medicine

[10] Yang Ming Hospital,Division of Gastroenterology and Hepatology, Department of Internal Medicine

[11] China Medical University Beigang Hospital,Division of Gastroenterology and Hepatology, Department of Internal Medicine

[12] Taichung Veterans General Hospital,Division of Gastroenterology and Hepatology, Department of Internal Medicine

[13] Chung Shan Medical University,School of Medicine

[14] National Chung Hsing University,Institute of Biomedical Sciences

[15] China Medical University Hospital,Center for Digestive Medicine, Department of Internal Medicine

[16] China Medical University,School of Medicine

[17] Chung Shan Medical University Hospital,Division of Gastroenterology and Hepatology, Department of Internal Medicine

[18] Taipei Medical University Hospital,Division of Gastroenterology and Hepatology, Department of Internal Medicine

[19] Taipei Medical University,Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine

[20] Taipei Medical University,Graduate Institute of Clinical Medicine, College of Medicine

[21] Fu Jen Catholic University Hospital,Division of Gastroenterology and Hepatology, Department of Internal Medicine

[22] National Defense Medical Center,Division of Gastroenterology, Department of Internal Medicine, Tri

[23] National Taiwan University College of Medicine,Service General Hospital

[24] National Taiwan University College of Medicine,Department of Tropical Medicine and Parasitology

来源：

Hepatology International | 2021年 / 15卷

关键词：

Hepatitis C virus; Direct acting antiviral; Sofosbuvir; Velpatasvir; Sustained virologic response; Adverse event; East Asian; Effectiveness; Safety; Pangenotypic;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：338 / 349

页数：11

共 50 条

[41] EFFICACY AND SAFETY OF 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 3 HEPATITIS C VIRUS-INFECTED PATIENTS: A REAL-WORLD STUDY OF CHINA AND SAFETY OF 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 3 HEPATITIS C VIRUS-INFECTED PATIENTS: A REAL-WORLD STUDY OF CHINA
Yue, Wei
Liu, Li
Xiao, An
Du, Yingrong
Gao, Jianpeng
Liu, Min
Wang, Yilan
Che, Meng
Guo, Jiaxiang
Li, Junyi
Geng, Jiawei
HEPATOLOGY, 2021, 74 : 589A - 589A
[42] Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study
Toshifumi Tada
Takashi Kumada
Hiroaki Okushin
Joji Tani
Koichi Takaguchi
Akemi Tsutsui
Hidenori Toyoda
Satoshi Yasuda
Kazufumi Dohmen
Atsushi Hiraoka
Kojiro Michitaka
Kazuhiro Nouso
Kazuya Kariyama
Soo Ryang Kim
Soo Ki Kim
Shinichi Fujioka
Shigeru Mikami
Yuto Watanabe
Tsutomu Tamai
Masanori Atsukawa
Norio Itokawa
Hironori Tanaka
Kunihiko Tsuji
Toru Ishikawa
Michitaka Imai
Ei Itobayashi
Hiroshi Shibata
Noritomo Shimada
Infectious Diseases and Therapy, 2021, 10 : 269 - 280
[43] Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study
Tada, Toshifumi
Kumada, Takashi
Okushin, Hiroaki
Tani, Joji
Takaguchi, Koichi
Tsutsui, Akemi
Toyoda, Hidenori
Yasuda, Satoshi
Dohmen, Kazufumi
Hiraoka, Atsushi
Michitaka, Kojiro
Nouso, Kazuhiro
Kariyama, Kazuya
Kim, Soo Ryang
Kim, Soo Ki
Fujioka, Shinichi
Mikami, Shigeru
Watanabe, Yuto
Tamai, Tsutomu
Atsukawa, Masanori
Itokawa, Norio
Tanaka, Hironori
Tsuji, Kunihiko
Ishikawa, Toru
Imai, Michitaka
Itobayashi, Ei
Shibata, Hiroshi
Shimada, Noritomo
INFECTIOUS DISEASES AND THERAPY, 2021, 10 (01) : 269 - 280
[44] Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection
Summers, B. B.
DRUGS OF TODAY, 2018, 54 (04) : 255 - 268
[45] Sofosbuvir, Velpatasvir , and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation
Cardona-Gonzalez, Maria G.
Goldman, Jason D.
Naravan, Lawrence
Brainard, Diana M.
Kowdley, Kris, V
HEPATOLOGY COMMUNICATIONS, 2018, 2 (12) : 1446 - 1450
[46] Sofosbuvir/velpatasvir for chronic hepatitis C infection in patients with transfusion-dependent thalassemia
Sharara, Ala I.
Rustom, Luma Basma O.
Marrache, Majd
Rimmani, Hussein H.
Daher, Halim Bou
Koussa, Suzanne
Taher, Ali
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (02) : E43 - E45
[47] Sofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infection
Nehra, V.
Rizza, S. A.
Temesgen, Z.
DRUGS OF TODAY, 2017, 53 (03) : 177 - 189
[48] EFFICACY AND SAFETY OF SOFOSBUVIR AND VELPATASVIR IN RENAL TRANSPLANT RECIPIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION
Greco, Rosita
Papalia, Teresa
Bonofiglio, Renzo
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
[49] Effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection: real-world data from Georgian hepatitis C elimination program
Tsertsvadze, T.
Chkhartishvili, N.
Abutidze, A.
Sharvadze, L.
Kerashvili, V.
Kamkamidze, G.
Zakalashvili, M.
Skaggs, B.
Gvinjilia, L.
Shadaker, S.
Nasrullah, M.
Gamkrelidze, A.
Kvaratskhelia, V.
Zeuzem, S.
Afdhal, N.
Arora, S.
Thornton, K.
Averhoff, F.
JOURNAL OF HEPATOLOGY, 2018, 68 : S281 - S282
[50] Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients
Belperio, Pamela S.
Shahoumian, Troy A.
Loomis, Timothy P.
Backus, Lisa I.
JOURNAL OF VIRAL HEPATITIS, 2019, 26 (08) : 980 - 990

← 1 2 3 4 5 →